BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 4764560)

  • 1. [Potentiation of L-Dopa in parkinsonism by means of an inhibitor of peripheral decarboxylation].
    Court J; Kase JC; Mena I; Palacios E
    Rev Med Chil; 1973 Jun; 101(6):452-5. PubMed ID: 4764560
    [No Abstract]   [Full Text] [Related]  

  • 2. [Advantages of the combination therapy (L-Dopa and decarboxylase inhibitors) in parkinsonism].
    Gattringer B; Steinhäusl H
    Wien Med Wochenschr; 1972 Jun; 122(25):369-71. PubMed ID: 4558132
    [No Abstract]   [Full Text] [Related]  

  • 3. [Therapy of Parkinsonism using L-dopa in combination with a decarboxylase inhibitor].
    Stammler A; Vielhaber K
    Fortschr Neurol Psychiatr Grenzgeb; 1972 Oct; 40(10):564-8. PubMed ID: 4565521
    [No Abstract]   [Full Text] [Related]  

  • 4. [Therapeutic association of L-dopa and an inhibitor of peripheral decarboxylase in Parkinsonism. Preliminary results].
    De Divitiis E; Cerillo A; Tata MR; Decina A
    Acta Neurol (Napoli); 1973; 28(2):208-12. PubMed ID: 4709076
    [No Abstract]   [Full Text] [Related]  

  • 5. Levodopa combined with MK 486 (L-alpha methyldopahydrazine)--a peripheral decarboxylase inhibitor in Parkinson's disease.
    Andrews CJ; Somerville B
    Med J Aust; 1974 Mar; 1(12):429-32. PubMed ID: 4598384
    [No Abstract]   [Full Text] [Related]  

  • 6. [2-year experiences with a combination treatment of Parkinsonism with L-dopa and a decarboxylase inhibitor (Benserazid, Ro 4-4602)].
    Birkmayer W; Linauer W; Mentasti M; Riederer P
    Wien Med Wochenschr; 1974 Jun; 124(22):340-4. PubMed ID: 4275492
    [No Abstract]   [Full Text] [Related]  

  • 7. [Experiences in the treatment of Parkinson's disease with a combination drug: L-dopa plus decarboxylase inhibitor (Ro 8-0576)].
    Steinhäusl H
    Wien Med Wochenschr; 1973 Jun; 123(26):433-5. PubMed ID: 4578743
    [No Abstract]   [Full Text] [Related]  

  • 8. [Treatment of Parkinsonism with oral L-DOPA combined with a decarboxylase inhibitor (Ro IV 46.02)].
    Tissot R; Gaillard JM; Guggisberg M; Gauthier G; de Ajuriaguerra J
    Presse Med (1893); 1969 Apr; 77(17):619-22. PubMed ID: 5785081
    [No Abstract]   [Full Text] [Related]  

  • 9. [Treatment of Parkinson's syndrome with L-dopa and a decarboxylase inhibitor].
    Lombardo L; de la Garza R; Ivan-Reynoso G
    Arch Invest Med (Mex); 1974; 5(2):105-16. PubMed ID: 4433198
    [No Abstract]   [Full Text] [Related]  

  • 10. [Therapy of Parkinson's syndrome with L-dopa per os combined with a decarboxylase inhibitor (Ro 46.02)].
    Tissot R; Gaillard JM; Guggisberg M; Gauthier G; De Ajuriaguerra J
    Neurol Neurocir Psiquiatr; 1969; 10(1):1-25. PubMed ID: 5406970
    [No Abstract]   [Full Text] [Related]  

  • 11. [Clinical studies on the treatment of parkinsonism with the L-dopa and decarboxylase inhibitor Ro-4-4602 association].
    Wajsbort J; Hemli JA; Alfandary I; Yahel M; Siegfried J
    Wien Med Wochenschr; 1971 Oct; 121(42):741-5. PubMed ID: 5115985
    [No Abstract]   [Full Text] [Related]  

  • 12. [Treatment of Parkinson's syndrome with L-dopa and its methylated derivatives: 3-OMD and 4-OMD associated with a decarboxylase inhibitor. Clinical and biochemical study].
    Tissot R; Bartholini G; Constantinidis J; Eisenring JJ; Geissbühler F; Yanniotis G; de Ajuriaguerra J
    Schweiz Med Wochenschr; 1973 Oct; 103(42):1466-74. PubMed ID: 4750149
    [No Abstract]   [Full Text] [Related]  

  • 13. [Treatment of parkinsonism with L-dopa and an L-aromatic amino acid inhibitor].
    Streifler M; Vardi J; Kesten M
    Harefuah; 1972 Nov; 83(9):362-4. PubMed ID: 4669737
    [No Abstract]   [Full Text] [Related]  

  • 14. [Drug therapy of Parkinson's syndrome. Clinical long-term study using L-dopa and the drug conbination L-dopa-decarboxylase inhibitor].
    Christiani K; Möller WD
    Munch Med Wochenschr; 1973 Apr; 115(16):711-3. PubMed ID: 4197759
    [No Abstract]   [Full Text] [Related]  

  • 15. [L-DOPA-and dopa-decarboxylase inhibitor combination for the treatment of Parkinsonism].
    Fujimori N; Kito S; Yamamoto M; Itoga E; Kosaka K
    Nihon Rinsho; 1974 Mar; 32(3):579-86. PubMed ID: 4859014
    [No Abstract]   [Full Text] [Related]  

  • 16. [Therapy of Parkinson's syndrome with L-dopa and a decarboxylase inhibitor (Ro 4-4602). Course in 71 patients].
    Ferel D
    Schweiz Med Wochenschr; 1972 Jan; 102(3):88-94. PubMed ID: 4551909
    [No Abstract]   [Full Text] [Related]  

  • 17. [Effect of the combined treatment of Parkinson patients with L-Dopa and a decarboxylase inhibitor (Ro4-4602). Quantitative analysis of bradykinesia by means of reaction time measurements].
    Kaufmann W; Butz P; Wiesendanger M
    Dtsch Z Nervenheilkd; 1970; 197(1):85-100. PubMed ID: 5522871
    [No Abstract]   [Full Text] [Related]  

  • 18. [Treatment of Parkinson's disease with L-dopa combined with a decarboxylase inhibitor].
    Siegfried J; Klaiber R; Perret E; Ziegler WH
    Dtsch Med Wochenschr; 1969 Dec; 94(52):2678-81. PubMed ID: 4903342
    [No Abstract]   [Full Text] [Related]  

  • 19. [Treatment of parkinsonism with L-Dopa associated with decarboxylase inhibitors. II].
    Gauthier G; de Ajuriaguerra J; Simona B; Constantinidis J; Eisenring JJ; Krassoievitch M; Yanniotis G; Tissot R
    Rev Neurol (Paris); 1970 Nov; 123(5):297-319. PubMed ID: 5513630
    [No Abstract]   [Full Text] [Related]  

  • 20. [Decarboxylase inhibitor given in combination with l-dopa. A new therapeutic principal in parkinsonism].
    Dietrichson P
    Tidsskr Nor Laegeforen; 1973 Oct; 93(28):2113-5. PubMed ID: 4590070
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.